DE69610290D1 - Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin - Google Patents

Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin

Info

Publication number
DE69610290D1
DE69610290D1 DE69610290T DE69610290T DE69610290D1 DE 69610290 D1 DE69610290 D1 DE 69610290D1 DE 69610290 T DE69610290 T DE 69610290T DE 69610290 T DE69610290 T DE 69610290T DE 69610290 D1 DE69610290 D1 DE 69610290D1
Authority
DE
Germany
Prior art keywords
desethyloxybutynin
oxybutynin
incontinence
horn
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69610290T
Other languages
English (en)
Other versions
DE69610290T2 (de
Inventor
Gunnar Aberg
Cullough John R Mc
Yue Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,542 external-priority patent/US5532278A/en
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of DE69610290D1 publication Critical patent/DE69610290D1/de
Application granted granted Critical
Publication of DE69610290T2 publication Critical patent/DE69610290T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
DE69610290T 1995-01-31 1996-01-25 Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin Expired - Fee Related DE69610290T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,542 US5532278A (en) 1995-01-31 1995-01-31 Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US08/480,194 US5677346A (en) 1995-01-31 1995-06-07 Treating urinary incontinence using (S)-desethyloxybutynin
PCT/US1996/001053 WO1996023492A1 (en) 1995-01-31 1996-01-25 Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin

Publications (2)

Publication Number Publication Date
DE69610290D1 true DE69610290D1 (de) 2000-10-19
DE69610290T2 DE69610290T2 (de) 2001-03-29

Family

ID=27009434

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69610290T Expired - Fee Related DE69610290T2 (de) 1995-01-31 1996-01-25 Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin

Country Status (25)

Country Link
US (1) US5677346A (de)
EP (1) EP0806948B1 (de)
JP (1) JPH11511730A (de)
KR (1) KR100390271B1 (de)
CN (1) CN1151786C (de)
AT (1) ATE196252T1 (de)
AU (1) AU706741B2 (de)
BR (1) BR9607001A (de)
CA (1) CA2211400C (de)
CZ (1) CZ290093B6 (de)
DE (1) DE69610290T2 (de)
DK (1) DK0806948T3 (de)
ES (1) ES2150663T3 (de)
FI (1) FI973163A (de)
GR (1) GR3034974T3 (de)
HK (1) HK1017986A1 (de)
HU (1) HUP9800794A3 (de)
NO (1) NO315927B1 (de)
NZ (1) NZ303372A (de)
PL (1) PL182768B1 (de)
PT (1) PT806948E (de)
RU (1) RU2181589C2 (de)
SK (1) SK283313B6 (de)
UA (1) UA45387C2 (de)
WO (1) WO1996023492A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
US6123961A (en) * 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
CA2315843A1 (en) * 1997-12-31 1999-07-08 Sepracor Inc. S-procyclidine for treating urinary incontinence
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6013830A (en) * 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
CZ302630B6 (cs) * 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
EP1191930A2 (de) 1999-05-20 2002-04-03 Sepracor Inc. Verfahren zur behandlung von asthma mit s-oxybutynin
US6432446B2 (en) * 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US6521724B2 (en) 2000-03-10 2003-02-18 E. I. Du Pont De Nemours And Company Polymerization process
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
ATE488233T1 (de) * 2000-04-26 2010-12-15 Watson Pharmaceuticals Inc Verminderung der nebenwirkungen bei der oxybutynin-therapie
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CN101108176A (zh) * 2000-06-07 2008-01-23 沃特森药物公司 用(r)-奥昔布宁和(r)-去乙基奥昔布宁治疗平滑肌机能亢进
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ES2283425T3 (es) * 2000-08-03 2007-11-01 Antares Pharma Ipl Ag Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados.
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
DE10103262A1 (de) * 2001-01-25 2002-08-01 Axel Schmidt-Dossi Arzneimittel gegen Blasenfunktionsstörung
DE60234318D1 (de) 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
CA2442281C (en) * 2001-03-27 2010-06-08 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
CA2464217A1 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
JP2005516992A (ja) * 2001-12-21 2005-06-09 ブリッジ ファーマ、インコーポレイテッド オキシブチニンの非心律動異常惹起性代謝物
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CA2688542C (en) * 2007-05-30 2016-07-12 Michael J. Martin Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG11201404776PA (en) 2012-02-09 2014-09-26 Altherx Inc Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
CN104116760A (zh) * 2014-07-14 2014-10-29 玉庆花 一种治疗遗尿的口服液
JP2017537165A (ja) 2014-12-03 2017-12-14 ヴェリセプト セラピューティクス、インク． 下部尿路系症状を対象とした徐放性ソラベグロンの組成物及び使用方法
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (de) * 1960-07-26
BE902605A (fr) * 1985-06-06 1985-09-30 Therabel Res S A N V Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
JP3066515B2 (ja) * 1992-11-11 2000-07-17 久光製薬株式会社 尿失禁治療用経皮投与製剤
EP0721348B1 (de) * 1993-09-29 1999-09-01 Alza Corporation Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern

Also Published As

Publication number Publication date
FI973163A0 (fi) 1997-07-30
CA2211400C (en) 2007-01-23
PT806948E (pt) 2001-02-28
JPH11511730A (ja) 1999-10-12
HUP9800794A3 (en) 1999-05-28
KR100390271B1 (ko) 2003-10-04
SK103597A3 (en) 1999-03-12
UA45387C2 (uk) 2002-04-15
SK283313B6 (sk) 2003-05-02
RU2181589C2 (ru) 2002-04-27
PL182768B1 (pl) 2002-02-28
CN1179714A (zh) 1998-04-22
US5677346A (en) 1997-10-14
NO973516D0 (no) 1997-07-30
NZ303372A (en) 1999-01-28
FI973163A (fi) 1997-09-30
NO315927B1 (no) 2003-11-17
ATE196252T1 (de) 2000-09-15
CA2211400A1 (en) 1996-08-08
CZ290093B6 (cs) 2002-05-15
GR3034974T3 (en) 2001-02-28
WO1996023492A1 (en) 1996-08-08
BR9607001A (pt) 1997-10-28
HK1017986A1 (en) 1999-12-10
CN1151786C (zh) 2004-06-02
AU4966496A (en) 1996-08-21
NO973516L (no) 1997-08-07
AU706741B2 (en) 1999-06-24
EP0806948A1 (de) 1997-11-19
DE69610290T2 (de) 2001-03-29
MX9705820A (es) 1997-10-31
PL321498A1 (en) 1997-12-08
CZ242197A3 (en) 1997-12-17
EP0806948B1 (de) 2000-09-13
ES2150663T3 (es) 2000-12-01
HUP9800794A2 (hu) 1998-07-28
DK0806948T3 (da) 2000-12-18

Similar Documents

Publication Publication Date Title
DE69610290T2 (de) Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin
CA2257121A1 (en) Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
SE9503924D0 (sv) Novel opioid peptides
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
NO20000093L (no) (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
WO1999033454A3 (en) S-procyclidine for treating urinary incontinence
WO2000076490A3 (en) Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
EP0324348A3 (de) Piperidincarboxamid-Derivate zur Behandlung von Bradycardien und Bradyarrhythmien
TW218014B (en) A new therapeutically active compound
WO1999033453A3 (en) R-procyclidine for treating urinary incontinence
JO1738B1 (en) A new therapeutically active compound
ATE145133T1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)- ester-verbindungen zur herstellung eines arzneimittels zur behandlung der neuromuskuläre inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee